Essential Pharma buys ocular and postpartum therapies from Novartis

Essential Pharma, a portfolio company of Gyrus Capital, has acquired on December 8, 2021, the worldwide rights – except for the USA and India – to iopidine for the adjunctive treatment of glaucoma, and methergine for treating post-partum hemorrhage from Novartis. The products are sold in over 50 countries worldwide, and their acquisition brings significant expansion to Essential Pharma’s portfolio and will complement the latter's market presence particularly in Europe, the Middle East, Africa and Asia and allow for further expansion of sales and distribution channels in these territories.

Lenz & Staehelin advised Essential Pharma in this transaction.

The Lenz & Staehelin team consisted of partners Andreas Rötheli (M&A) and Sevan Antreasyan (IP, Commercial and Contracts) as well as associate Lara Alec and junior associates Alix Lauener and Noé Luisoni (all Corporate and M&A) and Anne-Laure Laplace (IP, Commercial and Contracts)